Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

Status Completed

Clinical Trial Summary

The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients. Other goals of this study are to determine if the vaccine can cause an immune response against patients' cancer cells and slow the growth of their brain tumors

Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the 5-year progression-free survival (PFS), using intradermal injections of autologous dendritic cells harvested from peripheral blood precursors and pulsed (co-cultured) with tumor lysate derived from surgical tissues in patients with low-grade gliomas. SECONDARY OBJECTIVES: I. To monitor overall survival (OS), and cellular immune responses in brain tumor patients injected with tumor lysate-pulsed dendritic cells. OUTLINE: Patients receive tumor lysate-pulsed autologous dendritic cell vaccine intradermally (ID) on days 0, 14, and 28. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01635283
Study type	Interventional
Source	Jonsson Comprehensive Cancer Center
Contact
Status	Completed
Phase	Phase 2
Start date	January 10, 2012
Completion date	May 13, 2016

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02194452` - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors	N/A
Completed	`NCT00238303` - Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	Phase 2
Completed	`NCT02015819` - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas	Phase 1
Completed	`NCT00045708` - A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas	Phase 1/Phase 2
Active, not recruiting	`NCT03890952` - Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma	Phase 2
Terminated	`NCT01814813` - Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery	Phase 2
Terminated	`NCT01575275` - Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme	Phase 2
Terminated	`NCT01996527` - 3T MRI Biomarkers of Glioma Treatment Response	Early Phase 1
Terminated	`NCT01103375` - Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma	Phase 1
Completed	`NCT00459381` - Pazopanib in Treating Patients With Recurrent Glioblastoma	Phase 2
Completed	`NCT00016328` - CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme	Phase 2
Terminated	`NCT00006773` - Bortezomib in Treating Patients With Recurrent Glioma	Phase 1
Completed	`NCT01806675` - 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy	Phase 1/Phase 2
Terminated	`NCT01148966` - Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors	Phase 1
Completed	`NCT00492089` - Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer	Phase 2
Completed	`NCT01125046` - Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas	Phase 2
Completed	`NCT01894061` - NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma	Phase 2
Completed	`NCT01644955` - Carboplatin in Treating Patients With Recurrent High-Grade Gliomas	Phase 1
Terminated	`NCT01269411` - RO4929097 in Treating Patients With Recurrent Invasive Gliomas	Phase 1
Completed	`NCT00650923` - Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma	Phase 1